This study suggests that (18)F-FAZA may be a very useful radiopharmaceutical to image hypoxia in the tumour types selected. Especially the high uptake by gliomas was encouraging. Given the good imaging properties, including acceptable T/B ratios in the tumour categories studied, (18)F-FAZA could be considered as a very promising agent for assessing the hypoxic fraction of these tumour types.

No abstract

Noise levels observed in positron emission tomography (PET) images complicate their geometric interpretation. Post-processing techniques aimed at noise reduction may be employed to overcome this problem. The detailed characteristics of the noise affecting PET images are, however, often not well known. Typically, it is assumed that overall the noise may be characterized as Gaussian. Other PET-imaging-related studies have been specifically aimed at the reduction of noise represented by a Poisson or mixed Poisson + Gaussian model. The effectiveness of any approach to noise reduction greatly depends on a proper quantification of the characteristics of the noise present. This work examines the statistical properties of noise in PET images acquired with a GEMINI PET/CT scanner. Noise measurements have been performed with a cylindrical phantom injected with 11 C and well mixed to provide a uniform activity distribution. Images were acquired using standard clinical protocols and reconstructed with filtered-backprojection (FBP) and row-action maximum likelihood algorithm (RAMLA).Statistical properties of the acquired data were evaluated and compared to five noise models (Poisson, normal, negative binomial, log-normal, and gamma). Histograms of the experimental data were used to calculate cumulative distribution functions and produce maximum likelihood estimates for the parameters of the model distributions. Results obtained confirm the poor representation of both RAMLA-and FBP-reconstructed PET data by the Poisson distribution. We demonstrate that the noise in RAMLAreconstructed PET images is very well characterized by gamma distribution followed closely by normal distribution, while FBP produces comparable conformity with both normal and gamma statistics.

An analytical theory of photon propagation and detection in single-photon emission computed tomography (SPECT) for collimated detectors is developed from first principles. The total photon detection kernel is expressed as a sum of terms due to the primary and the Compton scattered photons. The primary as well as contributions due to every order of Compton scattering are calculated separately. The model accounts for the three-dimensional depth dependence of the collimator holes as well as for nonhomogeneous attenuation. No specific assumptions about the boundary or the homogeneity of the attenuating medium are made. The energy response of the detector is also modeled by the theory. Analytical expressions are obtained for various contributions to the photon detection kernel, and the multidimensional integrals involved are calculated using standard numerical integration methods. Theoretically calculated projections and scatter fractions for the primary and the first through second scattering orders are compared with our own experimental results for a small cylindrical primary radiation source immersed at various positions in a uniform cylindrical phantom. Also, theoretically calculated scatter fractions for a small spherical (pointlike) source in a uniform elliptic phantom are compared with experimental and Monte Carlo simulation results taken from the recent literature. The results from the analytical method are essentially exact and are free from the inaccuracies inherent in the numerical simulation methods used to deal with the photon propagation and detection problem in SPECT so far. The method developed here is unique in the sense that it provides accurate theoretical predictions of results averaged over an infinite number of simulations or experiments. We believe that our theory enhances an intuitive understanding of the complex image formation process in SPECT and is an important step toward solving the inverse problem, that of reconstructing the primary radiation source distribution from the measured gamma camera projections.

Single event spectra for five beta-emitting radionuclides (Lu-177, Cu-67, Re-186, Re-188, Y-90) were calculated for single cells from two source geometries. The first was a surface-bound isotropically emitting point source and the second was a bath of free radioactivity in which the cell was submerged. Together these represent a targeted intraperitoneal radionuclide therapy. Monoenergetic single event spectra were calculated over an energy range of 11 keV to 2500 keV using the EGSnrc Monte Carlo system. Radionuclide single event spectra were constructed by weighting monoenergetic single event spectra according to radionuclide spectra appropriate for each source geometry. In the case of surface-bound radioactivity, these were radionuclide beta decay spectra. For the free radioactivity, a continuous slowing down approximation spectrum was used that was calculated based on the radionuclide decay spectra. The frequency mean specific energy per event increased as the energy of the beta emitter decreased. This is because, at these energies, the stopping power of the electrons decreases with increasing energy. The free radioactivity produced a higher frequency mean specific energy per event than the corresponding surface-bound value. This was primarily due to the longer mean path length through the target for this geometry. This information differentiates the radionuclides in terms of the physical process of energy deposition and could be of use in the radionuclide selection procedure for this type of therapy.

PurposeThe decay characteristics of radionuclides in PET studies can impact image reconstruction. 44gSc has been the topic of recent research due to potential theranostic applications and is a promising radiometal for PET imaging. In this study, the reconstructed images from phantom measurements with scandium in a small-animal PET scanner are compared with 18F and two prominent radiometals: 64Cu and 68GaMethodsThree phantoms filled with 18F, 64C, 68Ga, and 44gSc were imaged in the Siemens Inveon PET scanner. The NEMA image quality phantom was used to determine the recovery coefficients (RCs), spill-over ratios (SORs), and noise (%SD) under typical pre-clinical imaging conditions. Image contrast was determined using a Derenzo phantom, while the coincidence characteristics were investigated using an NEC phantom. Three reconstruction algorithms were used, namely filtered back projection (FBP), ordered subset expectation maximization (OSEM), and maximum a-posteriori (MAP).ResultsImage quality parameters were measured for 18F, 64Cu, 68Ga, and 44gSc respectively; using FBP, the %SD are 5.65, 5.88, 7.28, and 7.70; the RCs for the 5-mm rod are 0.849, 1.01, 0.615, and 0.825; the SORs in water are 0.0473, 0.0595, 0.141, 0.0923; and the SORs in air are 0.0589, 0.0484, 0.0525, and 0.0509. The contrast measured in the 2.5-mm rods are 0.674, 0.637, 0.196, and 0.347. The NEC rate with 44gSc increased at a slower rate than 18F and 68Ga as a function of activity in the field of view.Conclusion44gSc demonstrates intermediate behavior relative to 18F and 68Ga with regard to RC and contrast measurements. It is a promising radionuclide for preclinical imaging.

In recent years, a number of approaches have been applied to the problem of deformable registration validation. However, the challenge of assessing a commercial deformable registration system – in particular, an automatic registration system in which the deformable transformation is not readily accessible – has not been addressed. Using a collection of novel and established methods, we have developed a comprehensive, four‐component protocol for the validation of automatic deformable image registration systems over a range of IGRT applications. The protocol, which was applied to the Reveal‐MVS system, initially consists of a phantom study for determination of the system's general tendencies, while relative comparison of different registration settings is achieved through postregistration similarity measure evaluation. Synthetic transformations and contour‐based metrics are used for absolute verification of the system's intra‐modality and inter‐modality capabilities, respectively. Results suggest that the commercial system is more apt to account for global deformations than local variations when performing deformable image registration. Although the protocol was used to assess the capabilities of the Reveal‐MVS system, it can readily be applied to other commercial systems. The protocol is by no means static or definitive, and can be further expanded to investigate other potential deformable registration applications.PACS numbers: 87.19.xj, 87.56.Da, 87.57.nj

Bone metastases in advanced breast cancer patients remains a significant treatment challenge. Bisphosphonates are now a routine first line treatment for prevention and treatment of skeletal damage caused by malignancies and, moreover, have shown an ability to transport therapeutic drugs to the bone. Here, we describe the effect of a conjugate between the potent anticancer drug gemcitabine and a bisphosphonate molecule (Gem/BP) in an animal model of breast cancer metastases. We have previously demonstrated the targeting of this compound to bone in normal mice using an analog labeled with the radionuclide 99mTc. Using a bone metastasis model in nude mice produced by intracardiac injection of the human breast cancer cell line MDA-MB-231BO, we examined the effect of Gem/BP and gemcitabine in reducing the frequency and severity of osteolytic bone lesions. High-resolution radiographs and microPET images showed that Gem/ BP reduced the number and size of bone metastases relative to the gemcitabine-treated and the untreated control groups. Histological examination of the humeri and femurs of the control and gemcitabine groups revealed large metastatic cancer lesions in the outer and inner cortices and the medullary cavities. In contrast, Gem/BP-treated mice showed occasional small wedge-shaped metastases under the periosteum of the outer cortex and very occasionally in the medulla. These findings suggest that Gem/BP should be further evaluated for use in the treatment of bone metastases in breast cancer.